The endocrine testing market size has grown strongly in recent years. It will grow from $2.33 billion in 2023 to $2.55 billion in 2024 at a compound annual growth rate (CAGR) of 9.4%. The growth observed in the historical period can be attributed to several key factors, including the discovery of hormones and endocrine pathways, the standardization of diagnostic tests, the implementation of public health initiatives, and the increased advocacy and empowerment of patients.
The endocrine testing market size is expected to see strong growth in the next few years. It will grow to $3.67 billion in 2028 at a compound annual growth rate (CAGR) of 9.6%. The anticipated growth in the forecast period can be attributed to various factors, including the growing prevalence of endocrine disorders, heightened defense spending, an aging population, increased awareness and early diagnosis initiatives, and heightened overall awareness regarding endocrine health. Key trends expected in the forecast period encompass advancements in biomarker detection techniques, the integration of omics technologies, the utilization of artificial intelligence and machine learning for diagnostic purposes, a focus on quality assurance and standardization measures, and an emphasis on collaborative research efforts and translational medicine approaches.
The upward trend in diabetes prevalence is anticipated to drive the growth of the endocrine testing market in the foreseeable future. Diabetes, a condition characterized by elevated blood sugar levels, is on the rise due to various factors such as unhealthy dietary patterns, sedentary lifestyles, genetic predisposition, and an aging population. Endocrine testing plays a crucial role in diabetes management, encompassing tests such as hemoglobin A1c, fasting plasma glucose, and C-peptide tests to diagnose the condition, monitor glucose levels, and evaluate insulin production and sensitivity. For instance, data from the International Diabetes Federation in 2021 revealed that approximately 537 million adults (aged 20-79 years) globally were living with diabetes. Projections indicate a further increase to 643 million by 2030 and 783 million by 2045. Consequently, the surge in diabetes prevalence is stimulating demand within the endocrine testing market.
Key players in the endocrine testing market are focusing on developing point-of-care testing solutions to enhance accessibility and efficiency in diagnosing endocrine disorders. Point-of-care testing enables rapid results, aiding in prompt diagnosis and management of conditions such as heart failure in patients displaying symptoms such as shortness of breath and fatigue. For example, in April 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, introduced a point-of-care NT-proBNP test in India. This test is specifically tailored for screening diabetes patients at risk of cardiovascular diseases such as heart failure (HF), facilitating early detection and intervention. It empowers clinicians to identify high-risk T2D patients promptly and initiate timely treatment discussions, ultimately leading to improved outcomes and patient well-being.
In October 2022, Tolmar, a US-based pharmaceutical company, acquired Jatenzo from Clarus Therapeutics, although the financial details remain undisclosed. This acquisition aligns with Tolmar's focus on pediatric endocrinology and men's health, augmenting their portfolio of specialty pharmaceutical products. Clarus Therapeutics, a US-based pharmaceutical company, specializes in developing and commercializing therapies for individuals with endocrine disorders.
Major companies operating in the endocrine testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, Roche Holding, Siemens Healthineers, Quest Diagnostics, Agilent Technologies Inc., PerkinElmer Inc., BioMérieux SA, Beckman Coulter Inc., Bio-Rad Laboratories Inc., SD Biosensor Inc., Qiagen N.V., Ortho Clinical Diagnostics, Kronus Inc., Randox Laboratories Ltd., Fujirebio Diagnostics Inc., Inova Diagnostics Inc., Sekisui Diagnostics LLC, Mercodia AB, ZEUS Scientific Inc., IBL International, Monobind Inc., Agilus Diagnostics, Tosoh Bioscience Inc., DiaSorin S.p.A.
North America was the largest region in the endocrine testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the endocrine testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the endocrine testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Endocrine testing involves the diagnostic assessment of hormone levels within the body, typically conducted through blood, urine, or saliva analyses, to evaluate the function of the endocrine system. These tests play a vital role in diagnosing a range of endocrine disorders, such as diabetes, thyroid disorders, adrenal insufficiency, and pituitary gland disorders, enabling healthcare providers to formulate appropriate treatment and management plans for affected patients.
The primary types of endocrine testing encompass various assessments including the estradiol (E2) test, follicle-stimulating hormone (FSH) test, human chorionic gonadotropin (HCG) hormone test, luteinizing hormone (LH) test, dehydroepiandrosterone sulfate (DHEAS) test, progesterone test, testosterone test, thyroid-stimulating hormone (TSH) test, prolactin test, among others. For instance, the Estradiol (E2) Test involves a blood test to measure estradiol levels in the body. These tests utilize diverse technologies such as tandem mass spectrometry, immunoassays, monoclonal and polyclonal antibody technologies, sensor technology, clinical chemistry, among others, and are commonly conducted in hospitals, clinical laboratories, diagnostic centers, and similar healthcare facilities.
The endocrine testing market research report is one of a series of new reports that provides endocrine testing market statistics, including endocrine testing industry global market size, regional shares, competitors with a endocrine testing market share, detailed endocrine testing market segments, market trends and opportunities, and any further data you may need to thrive in the endocrine testing industry. This endocrine testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The endocrine testing market consists of revenues earned by entities by providing services such as hormone level testing, thyroid function testing, diabetes testing, adrenal function testing, reproductive hormone testing, pituitary function testing, and bone metabolism testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The endocrine testing market also includes sales of assay kits, analyzers, point-of-care testing devices, reagents, software solutions, quality control materials, and calibrators and controls. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The endocrine testing market size is expected to see strong growth in the next few years. It will grow to $3.67 billion in 2028 at a compound annual growth rate (CAGR) of 9.6%. The anticipated growth in the forecast period can be attributed to various factors, including the growing prevalence of endocrine disorders, heightened defense spending, an aging population, increased awareness and early diagnosis initiatives, and heightened overall awareness regarding endocrine health. Key trends expected in the forecast period encompass advancements in biomarker detection techniques, the integration of omics technologies, the utilization of artificial intelligence and machine learning for diagnostic purposes, a focus on quality assurance and standardization measures, and an emphasis on collaborative research efforts and translational medicine approaches.
The upward trend in diabetes prevalence is anticipated to drive the growth of the endocrine testing market in the foreseeable future. Diabetes, a condition characterized by elevated blood sugar levels, is on the rise due to various factors such as unhealthy dietary patterns, sedentary lifestyles, genetic predisposition, and an aging population. Endocrine testing plays a crucial role in diabetes management, encompassing tests such as hemoglobin A1c, fasting plasma glucose, and C-peptide tests to diagnose the condition, monitor glucose levels, and evaluate insulin production and sensitivity. For instance, data from the International Diabetes Federation in 2021 revealed that approximately 537 million adults (aged 20-79 years) globally were living with diabetes. Projections indicate a further increase to 643 million by 2030 and 783 million by 2045. Consequently, the surge in diabetes prevalence is stimulating demand within the endocrine testing market.
Key players in the endocrine testing market are focusing on developing point-of-care testing solutions to enhance accessibility and efficiency in diagnosing endocrine disorders. Point-of-care testing enables rapid results, aiding in prompt diagnosis and management of conditions such as heart failure in patients displaying symptoms such as shortness of breath and fatigue. For example, in April 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, introduced a point-of-care NT-proBNP test in India. This test is specifically tailored for screening diabetes patients at risk of cardiovascular diseases such as heart failure (HF), facilitating early detection and intervention. It empowers clinicians to identify high-risk T2D patients promptly and initiate timely treatment discussions, ultimately leading to improved outcomes and patient well-being.
In October 2022, Tolmar, a US-based pharmaceutical company, acquired Jatenzo from Clarus Therapeutics, although the financial details remain undisclosed. This acquisition aligns with Tolmar's focus on pediatric endocrinology and men's health, augmenting their portfolio of specialty pharmaceutical products. Clarus Therapeutics, a US-based pharmaceutical company, specializes in developing and commercializing therapies for individuals with endocrine disorders.
Major companies operating in the endocrine testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, Roche Holding, Siemens Healthineers, Quest Diagnostics, Agilent Technologies Inc., PerkinElmer Inc., BioMérieux SA, Beckman Coulter Inc., Bio-Rad Laboratories Inc., SD Biosensor Inc., Qiagen N.V., Ortho Clinical Diagnostics, Kronus Inc., Randox Laboratories Ltd., Fujirebio Diagnostics Inc., Inova Diagnostics Inc., Sekisui Diagnostics LLC, Mercodia AB, ZEUS Scientific Inc., IBL International, Monobind Inc., Agilus Diagnostics, Tosoh Bioscience Inc., DiaSorin S.p.A.
North America was the largest region in the endocrine testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the endocrine testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the endocrine testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Endocrine testing involves the diagnostic assessment of hormone levels within the body, typically conducted through blood, urine, or saliva analyses, to evaluate the function of the endocrine system. These tests play a vital role in diagnosing a range of endocrine disorders, such as diabetes, thyroid disorders, adrenal insufficiency, and pituitary gland disorders, enabling healthcare providers to formulate appropriate treatment and management plans for affected patients.
The primary types of endocrine testing encompass various assessments including the estradiol (E2) test, follicle-stimulating hormone (FSH) test, human chorionic gonadotropin (HCG) hormone test, luteinizing hormone (LH) test, dehydroepiandrosterone sulfate (DHEAS) test, progesterone test, testosterone test, thyroid-stimulating hormone (TSH) test, prolactin test, among others. For instance, the Estradiol (E2) Test involves a blood test to measure estradiol levels in the body. These tests utilize diverse technologies such as tandem mass spectrometry, immunoassays, monoclonal and polyclonal antibody technologies, sensor technology, clinical chemistry, among others, and are commonly conducted in hospitals, clinical laboratories, diagnostic centers, and similar healthcare facilities.
The endocrine testing market research report is one of a series of new reports that provides endocrine testing market statistics, including endocrine testing industry global market size, regional shares, competitors with a endocrine testing market share, detailed endocrine testing market segments, market trends and opportunities, and any further data you may need to thrive in the endocrine testing industry. This endocrine testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The endocrine testing market consists of revenues earned by entities by providing services such as hormone level testing, thyroid function testing, diabetes testing, adrenal function testing, reproductive hormone testing, pituitary function testing, and bone metabolism testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The endocrine testing market also includes sales of assay kits, analyzers, point-of-care testing devices, reagents, software solutions, quality control materials, and calibrators and controls. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Endocrine Testing Market Characteristics3. Endocrine Testing Market Trends and Strategies32. Global Endocrine Testing Market Competitive Benchmarking33. Global Endocrine Testing Market Competitive Dashboard34. Key Mergers and Acquisitions in the Endocrine Testing Market
4. Endocrine Testing Market - Macro Economic Scenario
5. Global Endocrine Testing Market Size and Growth
6. Endocrine Testing Market Segmentation
7. Endocrine Testing Market Regional and Country Analysis
8. Asia-Pacific Endocrine Testing Market
9. China Endocrine Testing Market
10. India Endocrine Testing Market
11. Japan Endocrine Testing Market
12. Australia Endocrine Testing Market
13. Indonesia Endocrine Testing Market
14. South Korea Endocrine Testing Market
15. Western Europe Endocrine Testing Market
16. UK Endocrine Testing Market
17. Germany Endocrine Testing Market
18. France Endocrine Testing Market
19. Italy Endocrine Testing Market
20. Spain Endocrine Testing Market
21. Eastern Europe Endocrine Testing Market
22. Russia Endocrine Testing Market
23. North America Endocrine Testing Market
24. USA Endocrine Testing Market
25. Canada Endocrine Testing Market
26. South America Endocrine Testing Market
27. Brazil Endocrine Testing Market
28. Middle East Endocrine Testing Market
29. Africa Endocrine Testing Market
30. Endocrine Testing Market Competitive Landscape and Company Profiles
31. Endocrine Testing Market Other Major and Innovative Companies
35. Endocrine Testing Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Endocrine Testing Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on endocrine testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for endocrine testing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The endocrine testing market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Test Type: Estradiol (E2) Test; Follicle Stimulating Hormone (FSH) Test; Human Chorionic Gonadotropin (hCG) Hormone Test; Luteinizing Hormone (LH) Test; Dehydroepiandrosterone Sulfate (DHEAS) Test; Progesterone Test; Testosterone Test; Thyroid Stimulating Hormone (TSH) Test; Prolactin Test; Other Types2) By Technology: Tandem Mass Spectrometry; Immunoassay; Monoclonal & Polyclonal Antibody Technologies; Sensor Technology; Clinical Chemistry; Other Technologies
3) By End-User: Hospitals; Clinical Laboratories; Diagnostic Centers; Other End-Users
Key Companies Mentioned: Thermo Fisher Scientific Inc.; Abbott Laboratories; Roche Holding; Siemens Healthineers; Quest Diagnostics
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Roche Holding
- Siemens Healthineers
- Quest Diagnostics
- Agilent Technologies Inc.
- PerkinElmer Inc.
- BioMérieux SA
- Beckman Coulter Inc.
- Bio-Rad Laboratories Inc.
- SD Biosensor Inc.
- Qiagen N.V.
- Ortho Clinical Diagnostics
- Kronus Inc.
- Randox Laboratories Ltd.
- Fujirebio Diagnostics Inc.
- Inova Diagnostics Inc.
- Sekisui Diagnostics LLC
- Mercodia AB
- ZEUS Scientific Inc.
- IBL International
- Monobind Inc.
- Agilus Diagnostics
- Tosoh Bioscience Inc.
- DiaSorin S.p.A.
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 175 |
Published | July 2024 |
Forecast Period | 2024 - 2028 |
Estimated Market Value ( USD | $ 2.55 Billion |
Forecasted Market Value ( USD | $ 3.67 Billion |
Compound Annual Growth Rate | 9.6% |
Regions Covered | Global |